Abbott Laboratories(ABT)Earnings, Financials & Key Ratios

ABT•NYSE

$87.18

$151.59B mkt cap·11.4× P/E·Price updated May 6, 2026

SectorHealthcare IndustryMedical Devices Sub-IndustryCardiovascular and heart rhythm devices

AboutAbbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.Show more

Revenue$41.95B+4.6%
EBITDA$10.04B+3.8%
Net Income$13.4B+134.2%
EPS (Diluted)7.64+133.6%
Gross Margin50.83%+1.8%
EBITDA Margin23.94%-0.8%
Operating Margin16.27%+1.4%
Net Margin31.95%+123.9%
ROE30.91%+104.5%
ROIC9.9%-4.8%
Debt/Equity0.32-22.0%
Interest Coverage11.32+22.8%

Analysis→Technical→

ABT Key Insights

Abbott Laboratories (ABT) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Excellent 3Y average ROE of 21.7%
✓Strong 5Y profit CAGR of 29.4%
✓Strong Piotroski F-Score: 7/9
✓FCF machine: 15.1% free cash flow margin
✓11 consecutive years of dividend growth
✓Healthy dividend yield of 2.5%

✗Weaknesses

✗Weak momentum: RS Rating 14 (bottom 14%)
✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

ABT Price & Volume

Abbott Laboratories (ABT) stock price & volume — 10-year historical chart

Loading chart...

ABT Growth Metrics

Abbott Laboratories (ABT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years7.56%

5 Years5.63%

3 Years-0.88%

TTM6.37%

Profit CAGR

10 Years19.36%

5 Years29.45%

3 Years23.76%

TTM142.36%

EPS CAGR

10 Years17.68%

5 Years29.97%

3 Years24.7%

TTM142.5%

Return on Capital

10 Years9.34%

5 Years11.89%

3 Years11.82%

Last Year10.78%

ABT Recent Earnings

Abbott Laboratories (ABT) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 7/12 qtrs (58%)●Beat Revenue 8/12 qtrs (67%)

Q2 2026Latest

Apr 16, 2026

EPS

$1.15

Est $1.14

+0.9%

Revenue

$11.2B

Est $11.0B

+1.5%

Q1 2026

Jan 22, 2026

EPS

$1.50

Est $1.50

+0.0%

Revenue

$11.5B

Est $11.8B

-2.9%

Q4 2025

Oct 15, 2025

EPS

$1.30

Est $1.30

+0.0%

Revenue

$11.4B

Est $11.4B

-0.2%

Q3 2025

Jul 17, 2025

EPS

$1.26

Est $1.26

+0.0%

Revenue

$11.1B

Est $11.1B

+0.5%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	Apr 16, 2026	$1.15vs $1.14+0.9%	$11.2Bvs $11.0B+1.5%
Q1 2026	Jan 22, 2026	$1.50vs $1.50+0.0%	$11.5Bvs $11.8B-2.9%
Q4 2025	Oct 15, 2025	$1.30vs $1.30+0.0%	$11.4Bvs $11.4B-0.2%
Q3 2025	Jul 17, 2025	$1.26vs $1.26+0.0%	$11.1Bvs $11.1B+0.5%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	FCF Yield	Debt / Equity
MDTMedtronic plcDirect Competitor	99.73B	77.79	21.55	3.62%	13%	9.45%	5.2%	0.59
BSXBoston Scientific CorporationDirect Competitor	83.2B	55.98	28.86	19.87%	14.4%	12.4%	4.4%	0.51
BDXBecton, Dickinson and CompanyDirect Competitor	52.23B	144.17	24.73	8.23%	8.01%	6.93%	5.11%	0.76
BAXBaxter International Inc.Direct Competitor	8.65B	16.75	-9.57	5.72%	-9.7%	-16.5%	3.74%	1.64
EWEdwards Lifesciences CorporationDirect Competitor	47.8B	82.91	45.31	11.55%	17.64%	10.35%	2.79%	0.07
SYKStryker CorporationDirect Competitor	113.08B	295.25	35.15	11.16%	12.92%	15.04%	3.79%	0.66
DHRDanaher CorporationProduct Competitor	123.6B	174.63	34.65	2.9%	14.89%	7.06%	4.26%	0.35
TMOThermo Fisher Scientific Inc.Product Competitor	173.46B	466.76	26.31	3.91%	15.18%	13.23%	3.63%	0.76

Compare ABT vs Peers

Abbott Laboratories (ABT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs MDT

Most directly comparable listed peer for ABT.

Scale Benchmark

vs JNJ

Larger-name benchmark to compare ABT against a more recognizable public peer.

Peer Set

Compare Top 5

vs MDT, BSX, BDX, BAX

ABT Income Statement

Abbott Laboratories (ABT) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	TTM
Sales/Revenue	20.85B	27.39B	30.58B	31.9B	34.61B	43.08B	43.65B	40.11B	41.95B	43.84B
Revenue Growth %	2.2%	31.35%	11.64%	4.34%	8.48%	24.47%	1.34%	-8.12%	4.59%	6.37%
Cost of Goods Sold	9.61B	14.32B	14.76B	15.21B	17.23B	19.86B	21.33B	20.07B	20.63B	20.18B
COGS % of Revenue	46.08%	52.3%	48.25%	47.68%	49.79%	46.11%	48.86%	50.04%	49.17%	-
Gross Profit	11.24B▲ 0%	13.07B▲ 16.2%	15.82B▲ 21.1%	16.69B▲ 5.5%	17.38B▲ 4.1%	23.21B▲ 33.6%	22.32B▼ 3.8%	20.04B▼ 10.2%	21.32B▲ 6.4%	23.67B▲ 0%
Gross Margin %	53.92%	47.7%	51.75%	52.32%	50.21%	53.89%	51.14%	49.96%	50.83%	53.98%
Gross Profit Growth %	2.59%	16.2%	21.1%	5.5%	4.1%	33.59%	-3.84%	-10.24%	6.43%	-
Operating Expenses	8B	11.09B	11.98B	12.1B	12.09B	14.01B	13.96B	13.6B	14.47B	15.91B
OpEx % of Revenue	38.34%	40.5%	39.18%	37.93%	34.92%	32.53%	31.98%	33.91%	34.5%	-
Selling, General & Admin	6.64B	8.96B	9.69B	9.69B	9.67B	11.28B	11.11B	10.88B	11.65B	12.13B
SG&A % of Revenue	31.83%	32.73%	31.69%	30.38%	27.94%	26.18%	25.45%	27.13%	27.77%	-
Research & Development	1.36B	2.13B	2.29B	2.41B	2.42B	2.74B	2.85B	2.72B	2.82B	2.95B
R&D % of Revenue	6.51%	7.78%	7.48%	7.55%	6.99%	6.36%	6.53%	6.78%	6.73%	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	2M
Operating Income	3.25B▲ 0%	1.97B▼ 39.3%	3.84B▲ 94.9%	4.59B▲ 19.4%	5.29B▲ 15.2%	9.2B▲ 73.9%	8.36B▼ 9.1%	6.43B▼ 23.0%	6.83B▲ 6.1%	7.79B▲ 0%
Operating Margin %	15.58%	7.2%	12.57%	14.39%	15.29%	21.36%	19.16%	16.04%	16.27%	17.76%
Operating Income Growth %	10.17%	-39.3%	94.93%	19.43%	15.25%	73.88%	-9.11%	-23.04%	6.06%	-
EBITDA	4.6B	4.99B	7.12B	7.61B	8.62B	12.74B	11.63B	9.68B	10.04B	10.92B
EBITDA Margin %	22.07%	18.23%	23.29%	23.84%	24.9%	29.57%	26.64%	24.13%	23.94%	24.9%
EBITDA Growth %	4.09%	8.5%	42.64%	6.78%	13.32%	47.81%	-8.71%	-16.78%	3.77%	9.43%
D&A (Non-Cash Add-back)	1.35B	3.02B	3.28B	3.01B	3.33B	3.54B	3.27B	3.24B	3.22B	3.13B
EBIT	1.72B	3.11B	3.6B	4.89B	5.68B	8.62B	8.62B	7.36B	7.62B	8.67B
Net Interest Income	-205M	-756M	-624M	-724M	-662M	-367M	-132M	-313M	-259M	-130M
Interest Income	99M	124M	105M	94M	46M	43M	183M	385M	344M	321M
Interest Expense	304M	880M	729M	818M	708M	410M	315M	698M	603M	451M
Other Income/Expense	-1.84B	259M	-971M	-514M	-323M	-989M	-56M	229M	188M	351M
Pretax Income	1.41B▲ 0%	2.23B▲ 57.9%	2.87B▲ 28.8%	4.08B▲ 41.9%	4.97B▲ 21.9%	8.21B▲ 65.3%	8.31B▲ 1.2%	6.66B▼ 19.8%	7.01B▲ 5.2%	8.14B▲ 0%
Pretax Margin %	6.78%	8.15%	9.4%	12.78%	14.36%	19.06%	19.03%	16.61%	16.72%	18.56%
Income Tax	350M	1.88B	539M	390M	497M	1.14B	1.37B	941M	-6.39B	-5.84B
Effective Tax Rate %	24.77%	84.18%	18.76%	9.57%	10%	13.88%	16.53%	14.12%	-91.1%	-71.75%
Net Income	1.4B▲ 0%	477M▼ 65.9%	2.37B▲ 396.4%	3.69B▲ 55.7%	4.5B▲ 21.9%	7.07B▲ 57.3%	6.93B▼ 2.0%	5.72B▼ 17.5%	13.4B▲ 134.2%	13.98B▲ 0%
Net Margin %	6.71%	1.74%	7.74%	11.56%	12.99%	16.42%	15.88%	14.27%	31.95%	31.88%
Net Income Growth %	-68.35%	-65.93%	396.44%	55.7%	21.91%	57.31%	-1.95%	-17.45%	134.18%	142.36%
Net Income (Continuing)	1.06B	353M	2.33B	3.69B	4.47B	7.07B	6.93B	5.72B	13.4B	13.98B
Discontinued Operations	337M	124M	34M	0	24M	0	0	0	0	0
Minority Interest	179M	201M	198M	213M	219M	222M	219M	224M	237M	310M
EPS (Diluted)	0.94▲ 0%	0.27▼ 71.3%	1.34▲ 396.3%	2.06▲ 53.7%	2.50▲ 21.4%	3.94▲ 57.6%	3.91▼ 0.8%	3.27▼ 16.4%	7.64▲ 133.6%	7.99▲ 0%
EPS Growth %	-68.03%	-71.28%	396.3%	53.73%	21.36%	57.6%	-0.76%	-16.37%	133.64%	142.5%
EPS (Basic)	0.95	0.27	1.35	2.07	2.52	3.97	3.94	3.30	7.67	-
Diluted Shares Outstanding	1.48B	1.75B	1.77B	1.78B	1.79B	1.79B	1.76B	1.75B	1.75B	1.75B
Basic Shares Outstanding	1.47B	1.74B	1.76B	1.77B	1.77B	1.77B	1.75B	1.73B	1.73B	1.75B
Dividend Payout Ratio	109.93%	387.63%	83.36%	61.57%	56.95%	45.28%	47.73%	62.14%	28.62%	-

ABT Balance Sheet

Abbott Laboratories (ABT) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	TTM
Total Current Assets	26.78B	20.15B	14.63B	15.67B	20.44B	24.24B	25.22B	22.67B	23.66B	24.84B
Cash & Short-Term Investments	18.77B	9.61B	4.09B	4.14B	7.15B	10.25B	10.17B	7.28B	7.97B	7.73B
Cash Only	18.62B	9.41B	3.84B	3.86B	6.84B	9.8B	9.88B	6.9B	7.62B	7.51B
Short-Term Investments	155M	203M	242M	280M	310M	450M	288M	383M	351M	222M
Accounts Receivable	3.25B	5.25B	5.18B	5.42B	6.41B	6.49B	6.22B	6.57B	6.92B	10.4B
Days Sales Outstanding	56.85	69.95	61.86	62.07	67.65	54.97	51.99	59.74	60.25	72.6
Inventory	2.43B	3.6B	3.8B	4.32B	5.01B	5.16B	6.17B	6.57B	6.19B	6.71B
Days Inventory Outstanding	92.46	91.76	93.9	103.57	106.17	94.77	105.63	119.47	109.61	119.83
Other Current Assets	2.32B	1.69B	1.57B	1.79B	1.87B	2.35B	2.66B	2.26B	2.57B	0
Total Non-Current Assets	28.23B	56.1B	52.54B	52.22B	52.11B	50.96B	49.21B	50.54B	57.76B	59.34B
Property, Plant & Equipment	5.71B	7.61B	7.56B	8.97B	10.13B	10.11B	10.28B	11.28B	11.73B	11.5B
Fixed Asset Turnover	3.66x	3.60x	4.04x	3.56x	3.42x	4.26x	4.25x	3.56x	3.58x	3.85x
Goodwill	7.68B	24.02B	23.25B	23.2B	23.74B	23.23B	22.8B	23.68B	23.11B	23.97B
Intangible Assets	4.54B	21.47B	18.94B	17.02B	14.78B	12.74B	10.45B	8.81B	6.65B	5.59B
Long-Term Investments	2.95B	883M	897M	931M	1.03B	903M	766M	799M	886M	3.7B
Other Non-Current Assets	3.35B	2.12B	1.89B	2.1B	2.42B	3.97B	4.92B	5.97B	15.38B	66.84B
Total Assets	55.01B▲ 0%	76.25B▲ 38.6%	67.17B▼ 11.9%	67.89B▲ 1.1%	72.55B▲ 6.9%	75.2B▲ 3.6%	74.44B▼ 1.0%	73.21B▼ 1.6%	81.41B▲ 11.2%	84.18B▲ 0%
Asset Turnover	0.38x	0.36x	0.46x	0.47x	0.48x	0.57x	0.59x	0.55x	0.52x	0.53x
Asset Growth %	25.02%	38.61%	-11.9%	1.06%	6.87%	3.65%	-1.01%	-1.64%	11.2%	51.85%
Total Current Liabilities	6.66B	8.91B	9.01B	10.86B	11.91B	13.11B	15.49B	13.84B	14.16B	14.58B
Accounts Payable	1.18B	2.4B	2.98B	3.25B	3.95B	4.41B	4.61B	4.29B	4.2B	4.12B
Days Payables Outstanding	44.75	61.21	73.59	78.03	83.59	81.01	78.84	78.1	74.24	76.16
Short-Term Debt	1.32B	714M	207M	1.68B	461M	999M	2.48B	1.32B	1.75B	1.34B
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	3.22B	4.3B	4.34B	4.46B	5.72B	5.77B	6.5B	6.13B	5.91B	0
Current Ratio	4.02x	2.26x	1.62x	1.44x	1.72x	1.85x	1.63x	1.64x	1.67x	1.67x
Quick Ratio	3.65x	1.86x	1.20x	1.04x	1.30x	1.46x	1.23x	1.16x	1.23x	1.23x
Cash Conversion Cycle	104.56	100.5	82.17	87.6	90.23	68.73	78.79	101.11	95.63	116.28
Total Non-Current Liabilities	27.63B	36.24B	27.44B	25.72B	27.64B	26.07B	22.04B	20.55B	19.36B	18.34B
Long-Term Debt	20.68B	27.21B	19.36B	16.66B	18.53B	17.3B	14.52B	13.6B	12.63B	11.6B
Capital Lease Obligations	0	0	0	755M	902M	956M	943M	949M	896M	896M
Deferred Tax Liabilities	2.7B	2.01B	2.06B	2.13B	2.15B	2.07B	1.84B	1.22B	1.37B	1.37B
Other Non-Current Liabilities	4.25B	7.02B	6.02B	6.18B	6.06B	5.74B	4.74B	4.78B	4.46B	24.65B
Total Liabilities	31.95B	45.15B	36.45B	36.59B	39.55B	39.17B	37.53B	34.39B	33.51B	32.92B
Total Debt	22.01B	27.92B	19.57B	19.1B	19.89B	19.25B	17.95B	15.87B	15.28B	12.94B
Net Debt	3.39B	18.52B	15.72B	15.24B	13.05B	9.45B	8.06B	8.98B	7.66B	5.43B
Debt / Equity	1.06x	0.90x	0.64x	0.61x	0.60x	0.53x	0.49x	0.41x	0.32x	0.32x
Debt / EBITDA	4.78x	5.59x	2.75x	2.51x	2.31x	1.51x	1.54x	1.64x	1.52x	1.19x
Net Debt / EBITDA	0.74x	3.71x	2.21x	2.00x	1.51x	0.74x	0.69x	0.93x	0.76x	0.76x
Interest Coverage	10.69x	2.24x	5.27x	5.61x	7.47x	22.44x	26.55x	9.22x	11.32x	19.22x
Total Equity	20.72B▲ 0%	31.1B▲ 50.1%	30.72B▼ 1.2%	31.3B▲ 1.9%	33B▲ 5.4%	36.02B▲ 9.2%	36.91B▲ 2.4%	38.83B▲ 5.2%	47.9B▲ 23.4%	51.26B▲ 0%
Equity Growth %	-2.86%	50.11%	-1.21%	1.88%	5.44%	9.15%	2.45%	5.21%	23.37%	105.59%
Book Value per Share	13.97	17.78	17.36	17.57	18.48	20.14	20.92	22.20	27.40	29.31
Total Shareholders' Equity	20.54B	30.9B	30.52B	31.09B	32.78B	35.8B	36.69B	38.6B	47.66B	50.95B
Common Stock	13.03B	23.21B	23.51B	23.85B	24.14B	24.47B	24.71B	24.87B	25.15B	25.41B
Retained Earnings	25.57B	23.98B	24.56B	25.85B	27.63B	31.53B	35.26B	37.55B	47.26B	49.1B
Treasury Stock	-10.79B	-10.22B	-9.96B	-10.15B	-10.04B	-11.82B	-15.23B	-15.98B	-16.84B	-16.88B
Accumulated OCI	-7.26B	-6.06B	-7.59B	-8.46B	-8.95B	-8.37B	-8.05B	-7.84B	-7.91B	-6.68B
Minority Interest	179M	201M	198M	213M	219M	222M	219M	224M	237M	310M

ABT Cash Flow Statement

Abbott Laboratories (ABT) cash flow — operating, investing & free cash flow history

Line item	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	TTM
Cash from Operations	3.2B	5.57B	6.3B	6.14B	7.9B	10.53B	9.58B	7.26B	8.56B	8.56B
Operating CF Margin %	15.36%	20.34%	20.6%	19.23%	22.83%	24.45%	21.95%	18.1%	20.4%	-
Operating CF Growth %	7.99%	73.9%	13.11%	-2.6%	28.76%	33.31%	-9.04%	-24.21%	17.86%	40.12%
Net Income	1.38B	477M	2.37B	3.69B	4.5B	7.07B	6.93B	5.72B	13.4B	13.98B
Depreciation & Amortization	1.35B	3.02B	3.28B	3.01B	3.33B	3.54B	3.27B	3.24B	3.22B	3.13B
Stock-Based Compensation	310M	406M	477M	519M	546M	640M	685M	644M	673M	662M
Deferred Taxes	248M	-1.16B	293M	0	0	0	0	0	0	0
Other Non-Cash Items	1.43B	912M	32M	247M	425M	55M	215M	126M	482M	432M
Working Capital Changes	-1.51B	1.92B	-148M	-1.33B	-892M	-771M	-1.52B	-2.48B	-9.22B	-9.08B
Change in Receivables	-177M	-207M	-190M	-275M	-924M	-383M	-68M	-356M	-691M	-1.03B
Change in Inventory	-98M	249M	-514M	-593M	-493M	-456M	-1.41B	-232M	-58M	196M
Change in Payables	-652M	615M	747M	220M	1.77B	1.29B	420M	-760M	356M	0
Cash from Investing	-248M	-9.62B	-1.36B	-1.81B	-2.21B	-2.01B	-1.74B	-3.13B	-2.34B	-2.38B
Capital Expenditures	-1.12B	-1.14B	-1.39B	-1.64B	-2.18B	-1.89B	-1.78B	-2.2B	-2.21B	-2.2B
CapEx % of Revenue	5.38%	4.14%	4.56%	5.13%	6.29%	4.38%	4.07%	5.49%	5.26%	-
Acquisitions	-55M	-8.44B	48M	-122M	16M	-53M	48M	-837M	1M	-55M
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	42M	35M	48M	27M	19M	26M	22M	22M	9M	-118M
Cash from Financing	11.15B	-5.28B	-10.39B	-4.29B	-2.78B	-5.49B	-7.64B	-7.09B	-5.4B	-6.77B
Debt Issued (Net)	13.15B	-1.91B	-8.45B	-1.6B	-50M	-248M	-699M	-2.48B	-537M	-2.16B
Equity Issued (Net)	-1000K	-1000K	-1000K	-1000K	-1000K	-1000K	-1000K	-1000K	-1000K	-4M
Dividends Paid	-1.54B	-1.85B	-1.97B	-2.27B	-2.56B	-3.2B	-3.31B	-3.56B	-3.84B	-4.04B
Share Repurchases	-522M	-827M	-238M	-718M	-403M	-2.3B	-3.79B	-1.23B	-1.29B	-906M
Other Financing	53M	-1.05B	271M	298M	234M	255M	167M	167M	264M	334M
Net Change in Cash	13.62B▲ 0%	-9.21B▼ 167.6%	-5.56B▲ 39.6%	16M▲ 100.3%	2.98B▲ 18512.5%	2.96B▼ 0.6%	83M▼ 97.2%	-2.99B▼ 3697.6%	720M▲ 124.1%	-47M▲ 0%
Free Cash Flow	2.08B▲ 0%	4.43B▲ 113.0%	4.91B▲ 10.6%	4.5B▼ 8.3%	5.72B▲ 27.3%	8.65B▲ 51.1%	7.8B▼ 9.8%	5.06B▼ 35.2%	6.35B▲ 25.5%	6.92B▲ 0%
FCF Margin %	9.98%	16.19%	16.04%	14.1%	16.54%	20.08%	17.88%	12.61%	15.14%	15.78%
FCF Growth %	12.18%	113.02%	10.62%	-8.32%	27.26%	51.08%	-9.76%	-35.17%	25.54%	6.65%
FCF per Share	1.40	2.54	2.77	2.53	3.20	4.83	4.42	2.89	3.63	3.63
FCF Conversion (FCF/Net Income)	2.29x	11.68x	2.66x	1.66x	1.76x	1.49x	1.38x	1.27x	0.64x	0.49x
Interest Paid	181M	917M	845M	677M	549M	544M	563M	662M	604M	0
Taxes Paid	620M	570M	740M	930M	970M	1.94B	1.86B	1.48B	1.72B	0

ABT Key Ratios

Abbott Laboratories (ABT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	TTM
Return on Equity (ROE)	6.66%	1.84%	7.66%	11.89%	13.98%	20.49%	19.01%	15.11%	30.91%	27.26%
Return on Invested Capital (ROIC)	9.86%	4.01%	6%	7.41%	8.57%	15.08%	13.87%	10.4%	9.9%	9.9%
Gross Margin	53.92%	47.7%	51.75%	52.32%	50.21%	53.89%	51.14%	49.96%	50.83%	53.98%
Net Margin	6.71%	1.74%	7.74%	11.56%	12.99%	16.42%	15.88%	14.27%	31.95%	31.88%
Debt / Equity	1.06x	0.90x	0.64x	0.61x	0.60x	0.53x	0.49x	0.41x	0.32x	0.32x
Interest Coverage	10.69x	2.24x	5.27x	5.61x	7.47x	22.44x	26.55x	9.22x	11.32x	19.22x
FCF Conversion	2.29x	11.68x	2.66x	1.66x	1.76x	1.49x	1.38x	1.27x	0.64x	0.49x
Revenue Growth	2.2%	31.35%	11.64%	4.34%	8.48%	24.47%	1.34%	-8.12%	4.59%	6.37%

ABT SEC Filings & Documents

Abbott Laboratories (ABT) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Apr 17, 2026·SEC

Material company update

Apr 16, 2026·SEC

Material company update

Mar 23, 2026·SEC

10-K Annual Reports

FY 2026

Feb 20, 2026·SEC

FY 2025

Feb 21, 2025·SEC

FY 2024

Feb 16, 2024·SEC

10-Q Quarterly Reports

FY 2025

Oct 29, 2025·SEC

FY 2025

Jul 30, 2025·SEC

FY 2025

Apr 30, 2025·SEC

ABT Frequently Asked Questions

Abbott Laboratories (ABT) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Abbott Laboratories (ABT) reported $43.84B in revenue for fiscal year 2024. This represents a 338% increase from $10.01B in 1995.

Abbott Laboratories (ABT) grew revenue by 4.6% over the past year. Growth has been modest.

Yes, Abbott Laboratories (ABT) is profitable, generating $13.98B in net income for fiscal year 2024 (31.9% net margin).

Dividend & Returns

Yes, Abbott Laboratories (ABT) pays a dividend with a yield of 2.52%. This makes it attractive for income-focused investors.

Abbott Laboratories (ABT) has a return on equity (ROE) of 30.9%. This is excellent, indicating efficient use of shareholder capital.

Abbott Laboratories (ABT) generated $6.92B in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More ABT

Abbott Laboratories (ABT) financial analysis — history, returns, DCA and operating performance tools

Full ABT Stock Analysis

Analyst verdict, bull/bear case, risk factors and peer comparison

→

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Abbott Laboratories(ABT)Earnings, Financials & Key Ratios

ABT Key Insights

✓Strengths

✗Weaknesses

ABT Price & Volume

ABT Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

ABT Recent Earnings

ABT Peer Comparison

Compare ABT vs Peers

vs MDT

vs JNJ

Compare Top 5

ABT Income Statement

ABT Balance Sheet

ABT Cash Flow Statement

ABT Key Ratios

ABT SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

ABT Frequently Asked Questions

Explore More ABT

Full ABT Stock Analysis

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation